Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 7Lung Neoplasms 3Small Cell Lung Carcinoma 2Triple Negative Breast Neoplasms 1Sarcoma 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Mesothelioma 1Melanoma 1Kidney Neoplasms 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Adenocarcinoma 1

Interventions

Etoposide 156Carboplatin 146Cisplatin 106Topotecan 76durvalumab 52atezolizumab 51Irinotecan 45pembrolizumab 39Paclitaxel 34Nivolumab 33Radiotherapy 31PM 01183 25Drug Therapy 24anlotinib 23Gemcitabine 21apatinib 19Ipilimumab 18Docetaxel 17Temozolomide 16Platinum 16Radiosurgery 15Pemetrexed 14toripalimab 13tislelizumab 13olaparib 13Magnetic Resonance Spectroscopy 13Bevacizumab 13rovalpituzumab tesirine 11amrubicin 11Specimen Handling 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × Panobinostat × Thoracic × Clear all
NCT00958022 2017-06-22

Carboplatin and Etoposide Plus LBH589 for Small Cell Lung Cancer

University of Pittsburgh

Phase 1 Terminated
7 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT01222936 2010-10-18

LBH Phase II in Small Cell Lung Cancer (SCLC)

Southern Europe New Drug Organization

Phase 2 Completed
21 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡